MLPH Accelerates the Epithelial-Mesenchymal Transition in Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Prostate cancer (PC) is a leading cause of cancer mortality worldwide, with metastasis significantly worsening patient prognosis.
• Epithelial-mesenchymal transition (EMT) is a critical process in PC metastasis, but the underlying molecular mechanisms are not fully understood.
• Melanophilin (MLPH) has been implicated in PC, yet its specific role in cancer progression requires further elucidation.

Purpose of the Study:

• To investigate the role of melanophilin (MLPH) in prostate cancer (PC) progression and metastasis.
• To determine the effect of MLPH on epithelial-mesenchymal transition (EMT) in PC cells.
• To evaluate MLPH as a potential therapeutic target for advanced prostate cancer.

Main Methods:

• Bioinformatic analyses using the PROGgeneV2 database to correlate MLPH expression with patient survival.
• In vitro studies involving MLPH knockdown in PC cell lines to assess effects on migration, proliferation, and invasion using wound healing, migration, and invasion assays.
• In vivo studies to evaluate the impact of MLPH downregulation on tumor growth and metastasis in a preclinical model.
• Western blotting analysis to examine the expression of EMT markers (N-cadherin, E-cadherin) and β-catenin.

Main Results:

• High MLPH expression is associated with poor overall survival in prostate cancer patients.
• MLPH knockdown significantly inhibited PC cell migration, proliferation, and invasion in vitro.
• In vivo, MLPH downregulation reduced tumor growth rate and the number of lung metastatic nodules.
• MLPH knockdown reversed EMT by restoring E-cadherin expression, downregulating N-cadherin, and decreasing β-catenin levels.

Conclusions:

• Melanophilin (MLPH) plays a crucial role in promoting prostate cancer progression by driving the epithelial-mesenchymal transition (EMT).
• MLPH is a potential therapeutic target for inhibiting prostate cancer metastasis.
• Targeting MLPH may offer a novel strategy for treating advanced prostate cancer.